Timing matters: menstrual cycle may influence breast cancer treatment choices
NCT ID NCT05878314
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the menstrual cycle and preoperative hormone therapy affect a marker called Ki67 in women with early hormone-positive breast cancer. Researchers will also see if adding a genetic test (PAM50) changes treatment recommendations. About 504 women will participate, and the goal is to better personalize adjuvant therapy decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors personalize adjuvant treatment decisions for hormone-positive breast cancer patients.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly change patient outcomes or lead to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Women's Health
RECRUITINGTübingen, 72076, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging tracer could spot hidden cancers
- New hope for tough breast cancer: targeted drug HLX43 enters phase 2 trial
- New combo therapy aims to slow advanced breast cancer in BRCA patients
- New Triple-Drug attack shows promise for Hard-to-Treat breast cancer
- New hope for tough breast cancer: experimental drug EP0062 enters human trials
- New cancer drug candidate BG-68501 enters first human trials